Insmed
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 5 Sell calls were actually followed by a +76% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -8.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 6.4% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 79.7% | Better than 90% |
| Operating margin | -164.0% | Better than 6% |
| Net margin | -210.5% | Better than 5% |
| Return on equity | -249.3% | Better than 2% |
| Return on invested capital | -88.3% | Better than 3% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 12.4% | Better than 92% |
| 6-month return | 33.0% | Better than 90% |
| 12-month return (ex latest month) | -52.2% | Better than 3% |
| Distance below 52-week high | 33.6% | Better than 37% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.8x | Better than 80% |
| Debt to assets | 25.9% | Better than 47% |
| Interest coverage | -15.4x | Better than 11% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 94.1% | Better than 76% |
| Upside to average target | 34.7% | Better than 54% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 144.46
- Open
- 143.27
- Day range
- 140.99 - 150.00
- Avg price
- 144.02
- Volume
- 6.22M
- Turnover
- 895.27M
- Turnover ratei
- 2.85%
- Volume ratioi
- 1.38
- Amplitudei
- 6.24%
- 52-week rangei
- 90.39 - 212.75
Valuation
- P/Ei
- -22.01
- P/E (TTM)i
- -50.30
- P/Bi
- 42.70
- EPSi
- -6.42
- Book value / shi
- 3.31
- Net profit
- -1.41B
- Net assets
- 726.15M
Share structure
- Market cap
- 31.01B
- Float capi
- 30.80B
- Shares out
- 219.38M
- Float sharesi
- 217.94M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
33.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-81.98M net over the window
Short interest
- Shares short
- 14.08M
- % of floati
- 6.42%
- Days to coveri
- 3.56
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Insmed (INSM)?
Insmed last traded at 141.33. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Insmed's market cap?
About 31.01B.
What is the P/E ratio of Insmed?
The trailing twelve-month P/E is -50.30. The Valuation tab shows it against the stock's own five-year range.
Does Insmed pay a dividend?
Insmed does not currently pay a regular dividend.
Is Insmed a buy according to analysts?
The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 190.31, which implies 34.7% upside from the current price. This is not investment advice.
What is Insmed's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Insmed a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:34 · For reference only, not investment advice and not tailored to your situation.
Insmed discussion 0 comments